ArticleScientific reports2026
Mechanisms of FOXK1-regulated glycolipid metabolism in mediating TOX-induced histone lactylation to promote CD8⁺ T cell exhaustion in high-grade serous ovarian cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Histone lactylation: a novel epigenetic bridge linking cellular metabolism to benign and malignant gynecological diseases.Clinical epigenetics · 2026Review
- Lactate metabolism and lactylation in female reproductive diseases: From metabolic rewiring to biomarkers and translational therapeutics.Clinical and translational medicine · 2026Review
- Research progress on protein lactylation in female reproductive disease: molecular mechanisms, functions, and therapeutic implications.Frontiers in pharmacology · 2026Review
- Natural compounds targeting glycolysis and TME in ovarian cancer: from metabolic crosstalk to therapeutic potential.Frontiers in pharmacology · 2026Review
- Post-Translational Modifications in Cancer-Associated CD8⁺ T-Cell Exhaustion: Mechanisms and Therapeutic Opportunities.International journal of biological sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To determine whether FOXK1 induces CD8⁺ T cell exhaustion via histone lactylation in high-grade serous ovarian cancer (HGSOC). Cellular studies utilized qRT-PCR and Western blotting to compare FOXK1 expression in normal ovarian vs. cancer cells. Western blot assessed proteins linked to aerobic glycolysis, lipid metabolism, histone ubiquitination, and epithelial-mesenchymal transition (EMT). Cell migration/invasion were evaluated via scratch and Transwell assays. In vivo, a mouse ovarian cancer model was established. Lactate and lipid levels in supernatants/tissues were measured using Oil Red O and detection kits. TOX and glucose and lipid metabolism regulatory factors were analyzed by H&E staining and immunohistochemistry. The expression levels of immune related factors and the proportion of positive immune detection points in the supernatant of CD8+ T cell culture and tumor tissue were detected by ELISA kits and flow cytometry. Ovarian cancer cells showed elevated FOXK1, glycolysis proteins, lipid regulators, histone ubiquitination, EMT markers, lactate, and lipids compared to normal cells. Tumor tissues exhibited higher glycolysis proteins, lipid regulators, ubiquitination, and lipids than non-cancerous tissue. FOXK1 knockdown in SKOV3 cells reduced lactate, lipids, glucose uptake, glycolysis/lipid proteins, and inhibited proliferation/migration/invasion, while enhancing CD8 + T cell proliferation, immune checkpoint positivity, and immune factors, with decreased apoptosis. In mice, FOXK1 knockdown reduced tumor volume, TOX, glycolipid regulators, ubiquitination, and lipids, but increased immune factors and checkpoint-positive cells in tissues. FOXK1 regulates glycolipid metabolism and TOX histone lactylation, driving CD8 + T cell exhaustion, suggesting novel immunotherapy targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.